Abstract:RNA therapeutics comprise a diverse group of oligonucleotide-based drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) that can be designed to selectively interact with drug targets currently undruggable with small molecule-based drugs or monoclonal antibodies. Furthermore, RNA-based therapeutics have the potential to modulate entire disease pathways, and thereby represent a new modality with unprecedented potential for generating disease-modifying drugs for a wide variety of human diseases, including central nervous system (CNS) disorders. Here, we describe different strategies for delivering RNA drugs to the CNS and review recent advances in clinical development of ASO drugs and siRNA-based therapeutics for the treatment of neurological diseases and neuromuscular disorders.Abbreviations 2'-MOE: 2'-O-(2-methoxyethyl); 2'-O-Me: 2'-O-methyl; 2'-F: 2'-fluoro; AD: Alzheimer's disease; ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; ARC: Antibody siRNA Conjugate; AS: Angelman Syndrome; ASGRP: Asialoglycoprotein receptor; ASO: Antisense oligonucleotide; AxD: Alexander Disease; BBB: Blood brain barrier; Bp: Basepair; CNM: Centronuclear myopathies; CNS: Central Nervous System; CPP: Cell-penetrating Peptide; CSF: Cerebrospinal fluid; DMD: Duchenne muscular dystrophy; DNA: Deoxyribonucleic acid; FAP: Familial amyloid polyneuropathy; FALS: Familial amyotrophic lateral sclerosis; FDA: The United States Food and Drug Administration; GalNAc: N-acetylgalactosamine; GoF: Gain of function; hATTR: Hereditary transthyretin amyloidosis; HD: Huntington's disease; HRQOL: health-related quality of life; ICV: Intracerebroventricular; IT: Intrathecal; LNA: Locked nucleic acid; LoF: Loss of function; mRNA: Messenger RNA; MS: Multiple Sclerosis; MSA: Multiple System Atrophy; NBE: New Biological Entity; NCE: New Chemical Entity; NHP: Nonhuman primate; nt: Nucleotide; PD: Parkinson's disease; PNP: Polyneuropathy; PNS: Peripheral nervous system; PS: Phosphorothioate; RISC: RNA-Induced Silencing Complex; RNA: Ribonucleic acid; RNAi: RNA interference; s.c.: Subcutaneous; siRNA: Small interfering RNA; SMA: Spinal muscular atrophy; SMN: Survival motor neuron; TTR: Transthyretin

RNA variant assessment using transactivation and transdifferentiation

CRISPR single base editing, neuronal disease modelling and functional genomics for genetic variant analysis: pipeline validation using Kleefstra syndrome EHMT1 haploinsufficiency

Comparison of in silico strategies to prioritize rare genomic variants impacting RNA splicing for the diagnosis of genomic disorders

Identification of synonymous pathogenic variants in monogenic disorders by integrating exome with transcriptome sequencing

The clinical utility and diagnostic implementation of human subject cell transdifferentiation followed by RNA sequencing

variants in the non-coding spliceosomal snRNA gene are a frequent cause of syndromic neurodevelopmental disorders

Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease

Leveraging Splice-Affecting Variant Predictors and a Minigene Validation System to Identify Mendelian Disease-Causing Variants among Exon-Captured Variants of Uncertain Significance.

Experimental Assessment of Splicing Variants Using Expression Minigenes and Comparison with In Silico Predictions

Analysis of transcript-deleterious variants in Mendelian disorders: implications for RNA-based diagnostics

Identification of diagnostic candidates in Mendelian disorders using an RNA sequencing-centric approach

RNA Splicing Analysis Contributes to Reclassifying Variants of Uncertain Significance and Improves the Diagnosis of Monogenic Disorders

Defining the function of disease variants with CRISPR editing and multimodal single cell sequencing

Genome and RNA sequencing were essential to reveal cryptic intronic variants associated to defective ATP6AP1 mRNA processing

Clinical validation of RNA sequencing for Mendelian disorder diagnostics

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases

The human splicing code reveals new insights into the genetic determinants of disease

Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes

Identification and in-silico characterization of splice-site variants from a large cardiogenetic national registry

Polymorphisms Affecting Gene Transcription and Mrna Processing in Pharmacogenetic Candidate Genes: Detection Through Allelic Expression Imbalance in Human Target Tissues